Delcath Systems, Inc. :DCTH-US: Earnings Analysis: 2015 By the Numbers

Delcath Systems, Inc. reports financial results for the year ended December 31, 2015.

We analyze the earnings along side the following peers of Delcath Systems, Inc. – Insulet Corporation, ICU Medical, Inc., Merit Medical Systems, Inc., Unilife Corporation, Tandem Diabetes Care, Inc., Baxter International Inc. and Teleflex Incorporated (PODD-US, ICUI-US, MMSI-US, UNIS-US, TNDM-US, BAX-US and TFX-US) that have also reported for this period.

Highlights

  • Gross margins widened from -16.84% to 55.90% compared to the same period last year, operating (EBITDA) margins now -812.25% from -1,446.68%.
  • Year-on-year change in operating cash flow of -5.58% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings decline largely a result of non-operational activity, pretax margins improved from -1,625.91% to -841.67%.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2011 2012 2013 2014 2015
Relevant Numbers (Annual)
Revenues 0 0.35 0.79 1.07 1.75
Revenue Growth (YOY) N/A N/A N/A N/A N/A
Earnings -30.89 -51.87 -30.32 -17.38 -14.7
Earnings Growth (YOY) 33.84 -67.94 41.54 42.68 15.4
Net Margin N/A -14990.75 -3838.48 -1625.91 -841.67
EPS -10.88 -13.6 -4.96 -1.84 -0.91
Return on Equity -111.93 -224.96 -121.03 -72.05 -109.95
Return on Assets -71.98 -157.86 -89.75 -57.12 -74.46

Access our Ratings and Scores for Delcath Systems, Inc.


Earnings Growth Analysis

The company’s earnings growth was influenced by year-on-year improvement in gross margins from -16.84% to 55.90% as well as better cost controls. As a result, operating margins (EBITDA margins) rose from -1,446.68% to -812.25% compared to the same period last year. For comparison, gross margins were -16.84% and EBITDA margins were -1,446.68% in the last reporting period.

Gross Margin Versus EBITDA Margin


Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

DCTH-US‘s improvement in gross margin has been accompanied by an improvement in its balance sheet as well. This suggests that gross margin improvements are likely from operating decisions and not accounting gimmicks. Its working capital days have declined to 2,682.55 days from 7,645.88 days for the same period last year.

Gross Margin Versus Working Capital Days


Cash Versus Earnings – Sustainable Performance?

DCTH-US‘s change in operating cash flow of -5.58% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth


Margins

The company’s earnings decline is largely a result of non-operational activity. As a matter of fact, the company showed increases in operating (EBIT) and pretax margins. EBIT margins improved from -1,536.30% to -847.57% and pretax margins widened from -1,625.91% to -841.67%.

EBIT Margin Versus PreTax Margin
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Delcath Systems, Inc.


Company Profile

Delcath Systems, Inc. is a pharmaceutical and medical device company, which is focused on oncology and liver cancer therapy. Its proprietary drug and device combination product, Delcath Hepatic Delivery System is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The company also initiated plans to investigate the Melblez kit for primary liver cancer; and focuses on the treatment of primary and metastatic liver cancers. Its proprietary product also delivers and filters melphalan hydrochloride under the trade name Delcath Hepatic CHEMOSAT Delivery System. Delcath Systems was founded on August 5, 1988 and is headquartered in New York, NY.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of DCTH-US.